Asthma and Allergy Foundation of America

AAFA Joins Advocates on Capitol Hill in Support of Dillon’s Law and Expanded Access to Epinephrine

Retrieved on: 
Thursday, October 26, 2023
Asthma and Allergy Foundation of America, Anaphylaxis, Child, Mishicot High School, Dingell, Life, Allergy, Jon Mueller, Legislation, Face, Adrenaline, AAFA, Asthma, Risk, Epinephrine autoinjector, Death, Parent, Pharmaceutical industry

Dillon's Law is named after Dillon Mueller, an 18-year-old boy whose life was tragically cut short due to a severe allergic reaction to a bee sting.

Key Points: 
  • Dillon's Law is named after Dillon Mueller, an 18-year-old boy whose life was tragically cut short due to a severe allergic reaction to a bee sting.
  • Dillon had never experienced such a reaction before and did not have a prescription for epinephrine.
  • “The Dillon Mueller case is exactly why we need to expand access to rescue medication like epinephrine to treat anaphylaxis,” said AAFA president and CEO Kenneth Mendez.
  • Scott Walker at Mishicot High School in December 2017 and we then began our ‘Do it for Dillon’ epinephrine training program.

Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children

Retrieved on: 
Monday, September 25, 2023
Medical Devices, Health, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Asthma, University Hospitals Cleveland Medical Center, VAPO, Emergency department, CDC, Patient, Child, Asthma and Allergy Foundation of America, NHS, Periodic breathing, NYSE, Pharmaceutical industry, Vapotherm, DRS

The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England under the direction of Drs.

Key Points: 
  • The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England under the direction of Drs.
  • Children who presented to the Emergency Department with acute, severe, asthma exacerbations that did not respond to initial pharmacologic treatment were randomized to either HVNI or standard nasal oxygen therapy.
  • Eighty-six percent (19/22) of children treated with standard oxygen required escalation of therapy, while only 61% (17/28) of children treated with HVNI needed further escalation.
  • Almost 5 million children in the USA, and 1 million children in the UK have asthma, according to the CDC and NHS.

Allergy & Asthma Network Names Lynda Mitchell, CAE as Chief Executive Officer

Retrieved on: 
Friday, September 8, 2023
Allergy, Asthma, CAE, College, Education, Temple University, Patient, Health equity, Health information management, Research, Benedictine College, Science, Hospital, 2022 New Brunswick Liberal Association leadership election, ASAE, Health, Mitchell, Certified Associate in Project Management, Family, Asthma and Allergy Foundation of America, Caregiver, Management, Pharmaceutical industry, Nursing

FAIRFAX, Va., Sept. 8, 2023 /PRNewswire/ -- Allergy & Asthma Network today announced the appointment of Lynda Mitchell, MA, CAE, as its new Chief Executive Officer. The nationwide nonprofit patient advocacy organization advances its mission through outreach, education, advocacy and research to improve the lives and health of people living with allergies, asthma and related conditions.

Key Points: 
  • FAIRFAX, Va., Sept. 8, 2023 /PRNewswire/ -- Allergy & Asthma Network today announced the appointment of Lynda Mitchell, MA, CAE, as its new Chief Executive Officer.
  • "We are thrilled to appoint Lynda Mitchell as CEO of Allergy & Asthma Network," said Dennis Williams, co-chair of the organization's board of directors.
  • She steps into this role after joining Allergy & Asthma Network in 2019 and most recently serving as chief operations officer.
  • Prior to coming to Allergy & Asthma Network, Mitchell served as Chief Operating Officer, Asthma and Allergy Foundation of America, and she founded and served as CEO of Kids With Food Allergies Foundation.

Sami Nallamshetty, MD, FACAAI Uses Immunotherapy as a Powerful Tool to Treat Asthma and Allergies

Retrieved on: 
Friday, May 19, 2023
Allergen, Allergy, Hornet, Asthma, AAFA, Bee, Education, Sinusitis, Wheeze, Dermatitis, Season, Immunotherapy, Pollen, Research, National Institute of Food and Agriculture, William Frankland (allergist), Harvard Medical School, Patient, Dog, Asthma and Allergy Foundation of America, Dust, Immune system, Wiregrass, Cat, Agriculture, Hospital, Health, Wasp, Disease, Nursing, Pharmaceutical industry, Vaccine

It might even prevent the development of asthma in some children with seasonal allergies.

Key Points: 
  • It might even prevent the development of asthma in some children with seasonal allergies.
  • Both traditional and cluster immunotherapy (an accelerated version of allergy shots) are then administered in the office.
  • Clinical studies have shown they decrease symptoms, medication use and can even prevent new allergies and asthma in children.
  • "I am down from 5 allergy medications to 1 medication to treat my allergies!” proclaimed one of Dr. Nallamshetty’s patients.

The asthma & allergy friendly® Certification Program announces a new certification standard in response to increasing pollen counts and pollen allergies

Retrieved on: 
Tuesday, May 16, 2023
Allergen, Allergy, Asthma, AAFA, Atmosphere, Season, Allergic rhinitis, Post-nasal drip, Pollen, Volatile organic compound, Element, Ventilation, Certification, Climate change, ASL, Asthma and Allergy Foundation of America, Cochineal, Heating, ventilation, and air conditioning

WASHINGTON, May 16, 2023 /PRNewswire-PRWeb/ -- The asthma & allergy friendly® Certification Program, managed by Allergy Standards Ltd (ASL) and the Asthma and Allergy Foundation of America (AAFA), is excited to announce a new asthma & allergy friendly® certification standard for window-mounted pollen screens.

Key Points: 
  • WASHINGTON, May 16, 2023 /PRNewswire-PRWeb/ -- The asthma & allergy friendly® Certification Program, managed by Allergy Standards Ltd (ASL) and the Asthma and Allergy Foundation of America (AAFA), is excited to announce a new asthma & allergy friendly® certification standard for window-mounted pollen screens.
  • Pollen is the most common source of seasonal allergies and can trigger allergic asthma," shared Kenneth Mendez, CEO and president of AAFA.
  • The new window-mounted pollen screen certification standard is an important step to promote accessible options to people with asthma and allergies."
  • It is recommended that people with pollen allergies keep their windows closed during pollen season or at peak pollen times.

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

Retrieved on: 
Wednesday, May 10, 2023
The New England Journal of Medicine, Caregiver, Peanut allergy, Asthma and Allergy Foundation of America, Prevalence, Food allergy, Parent, Anxiety, Aes, Food, Quality of life, Apple QuickTake, Human, MBA, NEJM, Children's Hospital Colorado, Asthma, DBV, Swimming, Allergy, Editorial, Patient, Adrenaline, Master of Science, Immune system, DBV Technologies, FDA, Allergen, Peanut, Safety, Pharmaceutical industry, Vaccine, Euronext

DBV is advancing regulatory efforts for Viaskin Peanut in toddlers ages 1 – 3 years old with a confirmed peanut allergy.

Key Points: 
  • DBV is advancing regulatory efforts for Viaskin Peanut in toddlers ages 1 – 3 years old with a confirmed peanut allergy.
  • “We are thrilled to see the EPITOPE Phase 3 data published in the New England Journal of Medicine, highlighting exciting results for toddlers with peanut allergy and their loved ones,” said Daniel Tassé, Chief Executive Officer of DBV Technologies.
  • “This publication comes shortly after receiving pre-BLA feedback from the FDA, which outlined the regulatory path for our Viaskin Peanut program in 1 – 3-year-olds.
  • Additionally, a shift towards less severe food challenge reactions was seen following 12 months of treatment with Viaskin Peanut.

arbOUR Products Earns asthma & allergy friendly® Certification for its Free+Clear Laundry Detergent

Retrieved on: 
Wednesday, May 10, 2023
Allergy, Asthma, AAFA, VOC, Certification, Dust, ASL, Pet, MITES, Family, Allergen, Asthma and Allergy Foundation of America, Perfume

WASHINGTON, May 10, 2023 /PRNewswire-PRWeb/ -- The Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL) have announced that arbOUR Products Free+Clear laundry detergent has been CERTIFIED by the asthma & allergy friendly®Certification Program. The asthma & allergy friendly® Certification Program helps consumers identify products for the home that are more suitable for people with asthma and allergies. Products undergo independent testing to meet scientific standards established by the program. The certification mark is only awarded to those products that pass those standards.To earn the certification, Free+Clear laundry detergent passed rigorous scientific testing and demonstrated: Its ability to reduce over 95% of allergens related to pet dander and dust mites from fabrics washed with the detergent.

Key Points: 
  • WASHINGTON, May 10, 2023 /PRNewswire-PRWeb/ -- The Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL) have announced that arbOUR Products Free+Clear laundry detergent has been CERTIFIED by the asthma & allergy friendly®Certification Program.
  • The asthma & allergy friendly® Certification Program helps consumers identify products for the home that are more suitable for people with asthma and allergies.
  • "We congratulate arbOUR Products on earning the rigorous asthma & allergy friendly® Certification for its Free+Clear laundry detergent."
  • "About the asthma & allergy friendly® Certification Program
    The asthma & allergy friendly® Certification Program is a unique, groundbreaking collaboration between the Asthma and Allergy Foundation of America and Allergy Standards Limited.

Alen Air Purifiers Provide Relief for the 75 Million Americans Suffering From Allergies and Asthma Nationwide

Retrieved on: 
Tuesday, May 9, 2023
General Health, Health, Other Health, Medical Devices, Allergen, American Lung Association, Allergy, Congestion, Asthma, Irritant, Attack, Prevalence, Atmosphere, The Wall Street Journal, Wheeze, Pollen, Cough, LED, Immune system, Dust, Sneeze, MITES, HEPA, Research, Asthma and Allergy Foundation of America, Spore, Heating, ventilation, and air conditioning

Alen’s H13 medical-grade HEPA air filters capture 99.9% of airborne particles that can spur allergy and asthma symptoms and attacks.

Key Points: 
  • Alen’s H13 medical-grade HEPA air filters capture 99.9% of airborne particles that can spur allergy and asthma symptoms and attacks.
  • The American Lung Association recommends the use of air purifiers as one of several strategies for improving indoor air quality and reducing exposure to asthma triggers.
  • Research shows that air purifiers alleviate seasonal allergies and asthma symptoms by removing the allergens and irritants that trigger these conditions from the air.
  • Alen’s air purifiers are designed to run 24/7, constantly monitoring air quality to provide the greatest allergy relief year-round.

AAFA Announces New Health Equity Program Sites Serving Communities Facing Highest Burden of Asthma and Allergic Diseases

Retrieved on: 
Tuesday, May 2, 2023
Amgen, Asthma, Partnership, AAFA, Asthma and Allergy Foundation of America, Education, Health education, Regeneron Pharmaceuticals, Health equity, World Asthma Day, Research, Food security, AstraZeneca, School, CHW, Risk, Disease, Sanofi, HEAL, Transport, Health, Community health worker, Family, Pharmaceutical industry, Hospital, Nursing, Genentech

This initiative bolsters AAFA’s commitment to drastically reduce health disparities in communities with the heaviest asthma and allergy burden.

Key Points: 
  • This initiative bolsters AAFA’s commitment to drastically reduce health disparities in communities with the heaviest asthma and allergy burden.
  • AAFA’s HEAL program identifies and funds community-based health interventions tailored to at-risk populations most impacted by asthma and allergic diseases.
  • “What we learn from our HEAL sites is crucial to support our vision of creating sustainable solutions that foster health equity.
  • In 2020, the organization published a 15-year update to its Asthma Disparities in America report which outlined nearly 70 strategies to improve asthma health in underserved populations.

Tarkett's 2022 CSR Report demonstrates progress on key priorities: climate goals, circular economy and support to people & communities

Retrieved on: 
Monday, March 20, 2023
U.S. Department of Energy, Office of Inspector General, Science, Gold medal, Carbon accounting, Science Based Targets initiative, Developmental Leadership Program, Asthma, Office of Inspector General, U.S. Department of Health and Human Services, Carbon footprint, Electricity, Organic compound, Woman, Research, Corporate social responsibility, Recycling, Carbon, DOE, CSR, Certification, Organization, Renewable energy, FieldTurf, Climate change, Gold, Incineration, Water, Plasticizer, RS, CDP, Sport, Biophysical environment, Health, Safety, Asthma and Allergy Foundation of America, Management

Fully audited by an independent third party, this report outlines the company's significant sustainability performance.

Key Points: 
  • Fully audited by an independent third party, this report outlines the company's significant sustainability performance.
  • Doing more with less is our commitment, our mission and our mindset," said Fabrice Barthélemy, CEO of Tarkett.
  • Scope 1 & 2 greenhouse gas emissions from manufacturing operations were reduced by 41% versus 2019, notably through the increased purchase of renewable electricity.
  • Tarkett has made significant progress with ReStart®, its take-back and recycling program, by transforming end-of-use flooring and recycled materials into new floors.